Tafamidis (Fx-1006A): a first-in-class disease-modifying therapy for transthyretin familial amyloid

被引：0

作者：

Coelho, T. ^{[1
]}

Maia, L. ^{[1
]}

Martins da Silva, A. ^{[1
]}

Waddingtion-Cruz, M. ^{[2
]}

Plante-Bordeneuve, V. ^{[3
]}

Lozeron, P. ^{[4
]}

Suhr, O. B. ^{[5
]}

Campistol, J. ^{[6
]}

Conceicao, I. M. ^{[7
]}

Schmidt, H. ^{[8
]}

Trigo, P. ^{[9
]}

Packman, J. ^{[10
]}

Grogan, D. R. ^{[10
]}

机构：

[1] Hosp Santo Antonio, Dept Neurophysiol, Oporto, Portugal

[2] Univ Fed Rio de Janeiro, Univ Hosp, Neurol Serv, BR-21941 Rio De Janeiro, Brazil

[3] CHU Henri Mondor, Dept Neurol, F-94010 Creteil, France

[4] CHU Bicetre, Dept Neurol, Le Kremlin Bicetre, France

[5] Umea Univ Hosp, Dept Publ Hlth & Clin Med, S-90185 Umea, Sweden

[6] Hosp Clin Barcelona, Renal Transplant Unit, Barcelona, Spain

[7] Hosp Santa Maria, Dept Neurol, Lisbon, Portugal

[8] Univ Klinikum Munster, Munster, Germany

[9] FLENI, Buenos Aires, DF, Argentina

[10] FoldRx Pharmaceut Inc, Cambridge, MA USA

来源：

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS | 2010年 / 17卷

关键词：

D O I：

暂无

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：75 / 76

页数：2

共 50 条

[31] Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Mundayat, Rajiv
Stewart, Michelle
Alvir, Jose
Short, Sarah
Ong, Moh-Lim
Keohane, Denis
Rill, Denise
Sultan, Marla B.
NEUROLOGY AND THERAPY, 2018, 7 (01) : 87 - 101
[32] Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Rajiv Mundayat
Michelle Stewart
Jose Alvir
Sarah Short
Moh-Lim Ong
Denis Keohane
Denise Rill
Marla B. Sultan
Neurology and Therapy, 2018, 7 : 87 - 101
[33] A landmark clinical trial of a novel small molecule transthyretin (TTR) stabiliser, Fx-1006A, in patients with TTR amyloid polyneuropathy:: a phase II/III, randomised, double-blind, placebo-controlled study
Waddington-Cruz, M.
Coelho, T.
Maia, L.
da Silva, A. Martins
Plante-Bordeneuve, V.
Suhr, O.
Campistol, J.
Conceicao, I.
Schmidt, H.
Trigo, P.
Cros, D.
Grogan, D. Roy
Packman, J.
JOURNAL OF NEUROLOGY, 2008, 255 : 107 - 107
[34] Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial
Keohane, Denis
Schwartz, Jeffrey
Gundapaneni, Balarama
Stewart, Michelle
Amass, Leslie
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2017, 24 (01): : 30 - 36
[35] Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease (vol 10, pg 469, 2019)
De Simone, Angela
La Pietra, Valeria
Betari, Nibal
Petragnani, Nicola
Conte, Mariarosaria
Daniele, Simona
Pietrobono, Deborah
Martini, Claudia
Petralla, Sabrina
Casadei, Raffaella
Davani, Lara
Frabetti, Flavia
Russomanno, Pasquale
Novellino, Ettore
Montanari, Serena
Tumiatti, Vincenzo
Ballerini, Patrizia
Sarno, Federica
Nebbioso, Angela
Altucci, Lucia
Monti, Barbara
Andrisano, Vincenza
Milelli, Andrea
ACS MEDICINAL CHEMISTRY LETTERS, 2019, 10 (09): : 1357 - 1357
[36] Ioannou A. Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis (vol 18, pg 30, 2024)
Ioannou, Adam
HEART INTERNATIONAL, 2024, 18 (02): : 3 - 3
[37] Baseline predictors of major adverse events for transthyretin amyloidosis cardiomyopathy patients treated and untreated with disease-modifying therapy
Shahi, Karan
Miller, Robert J. H.
Dykstra, Steven
Feng, Yuanchao
Howlett, Jonathan G.
Kassam, Shireen
Veenhuyzen, Jan
White, James A.
Zepeda, Victor Jimenez
Fine, Nowell M.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 : S87 - S88
[38] BASELINE PREDICTORS OF MAJOR ADVERSE EVENTS FOR TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY PATIENTS TREATED AND UNTREATED WITH DISEASE-MODIFYING THERAPY
Shahi, Karan
Miller, Robert J. H.
Dykstra, Steven
Feng, Yuanchao
Howlett, Jonathan G.
Kassam, Shireen
Veenhuyzen, Jan
White, James
Fine, Nowell Mark
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 507 - 507
[39] What prompts a switch in disease-modifying therapy beyond first-line therapies?
Salter, A.
Tyry, T.
Belletti, D.
Malhotra, M.
Marrie, R.
Fox, R.
Cutter, G.
JOURNAL OF NEUROLOGY, 2012, 259 : S188 - S188
[40] Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis
Coerver, E. M. E.
Bourass, A.
Wessels, M. H. J.
van Kempen, Z. L. E.
Jasperse, M. M. S.
Tonino, B. A. R.
Barkhof, F.
Mostert, J.
Uitdehaag, B. M. J.
Killestein, J.
Strijbis, E. M. M.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 74

← 1 2 3 4 5 →